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Abstract 
 
PREVALENCE OF ANTI-DIABETIC AND ANTILIPIDEMIC MEDICATIONS IN 
CHILDREN AND ADOLESCENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS IN A 
VIRGINIA MEDICAID POPULATION 
 
by 
 
Della Varghese, PharmD 
 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Pharmaceutical Sciences at Virginia Commonwealth University 
 
 
Virginia Commonwealth University, 2013 
 
 
 
Major Director: Cynthia K Kirkwood, Pharm.D., BCPP 
Professor and Vice Chair for Education 
Department of Pharmacotherapy and Outcomes Science 
 
 
 
Objective: To determine if the prevalence of anti-diabetic and antilipidemic medication use 
among children treated with atypical antipsychotics is higher than those not treated with 
antipsychotics. 
Methods: Virginia Medicaid beneficiaries (2-17 years) continuously enrolled from August 1, 
2010 to July 31, 2011 with at least two prescription claims for atypical antipsychotics were the 
exposed group. All other subjects during the study period were the non-exposed group. 
Prevalence of anti-diabetic and antilipidemic medication use in both groups were computed and 
compared using Chi-square test (α=0.05).  
ix 
 
Results: A total of 299,593 and 4,922 subjects were identified as the non-exposed and exposed 
groups, respectively. Prevalence of anti-diabetic medication use was 0.32% in the unexposed and 
1.40% in the exposed group (p<0.0001). Prevalence of antilipidemic medication use was 0.09% 
in the unexposed and 0.35% in the exposed group (p<0.0001).  
Conclusion: Prevalence of anti-diabetic and antilipidemic medication use in the exposed group 
was significantly higher.  
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CHAPTER 1: Introduction  
 
A. Background 
One in four adults experience a psychiatric disorder in any given year.1,2 According to the 
National Survey on Drug Use and Health (NSDUH), 13.4% of adults in the United States (US) 
received treatment for mental illness in 2008.3 Mental health disorders have also been an issue 
among children and adolescents. One in ten children have a serious emotional disorder.1,4 
Antipsychotics have become the mainstay of treatment for a number of psychiatric disorders 
(e.g., psychosis, mood disorders, tic disorder, disruptive behavior disorder).5
A national survey conducted on youth in 2002 by Olfson et al. showed that there was a 6-fold 
increase in the number of office visits which resulted in a prescription for an antipsychotic 
medication between 1993 and 2002.
  
5 Another survey conducted by Olfson et al. from 2005 to 
2009 showed that there was a higher number of male patients among children and adolescents 
with office visits that resulted in the prescription of an antipsychotic agent.6 A larger percentage 
of the children had antipsychotic visits for disruptive behaviors disorders in comparison with 
schizophrenia and bipolar mania. Only a small proportion of the diagnoses for children who 
received an antipsychotic prescription were for a Food and Drug Administration (FDA) approved 
indication. The most common off-label indication treated was attention-deficit/hyperactivity 
disorder. Risperidone was the most commonly prescribed antipsychotic agent.
Use of second generation antipsychotics, or atypical antipsychotics, has increased because of the 
propensity to cause less adverse extrapyramidal symptoms (EPS) (i.e., dystonia, akathisia, 
pseudoparkinsonism, tardive dyskinesia) compared with the typical antipsychotics.
6 
7 Typical 
antipsychotics have been replaced by atypical antipsychotics, for the treatment of schizophrenia.  
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Studies have shown that atypical antipsychotics are at least as effective as the typical 
medications in the treatment of psychiatric disorders such as schizophrenia and there has been a 
rapid rise in the use of atypical antipsychotics.8-13 According to Olfson et al. of the total number 
of antipsychotics used by a pediatric population, about 92% was classified as atypical 
antipsychotics.
With increased use of atypical antipsychotics among children and adolescents, the FDA has 
approved some of these atypical agents for use in the pediatric population. As of 2011, 
aripiprazole, olanzapine, quetiapine, and risperidone have been labeled for use in children with 
bipolar mania (age 10-17 years; olanzapine:  13-17 years) and schizophrenia (13-17 years of 
age). Paliperidone is indicated for adolescents with schizophrenia (12-17 years). Aripiprazole 
and risperidone also have an indication for irritability/aggression associated with autism (6-17 
years of age).
5 
14
Recently, there has been increased concern about the metabolic adverse effects profile of the 
atypical agents in both adults and children. Evidence from adult studies suggest that atypical 
antipsychotics are linked with metabolic disturbances; most commonly weight gain, 
hyperglycemia, diabetes, and hyperlipidemia.
 Risperidone and aripiprazole were the first atypical antipsychotics to receive a 
pediatric indication in 2007.  
15 Newer studies indicate that these effects are also 
seen among children and adolescents.16 A study by Correll et al. showed that atypical 
antipsychotics were associated with weight gain, obesity, metabolic syndrome, dyslipidemia, 
glucose abnormalities, and decreased insulin sensitivity in children ages 4 through 19 
years. Metabolic syndrome in children and adolescents is characterized by 3 or more of the 
following criteria: a blood pressure greater than 90th percentile, obesity with Body Mass Index 
(BMI) greater than or equal to the 95th percentile, triglyceride levels greater than 110 mg/dL, 
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fasting glucose greater than or equal to 100 mg/dL, and a high density lipoprotein (HDL) less 
than 40 mg/dL.
Correll et al. reported that in children, atypical antipsychotics have the propensity to cause rapid 
weight gain and increases in BMI (>95
16 
th percentile) leading to complications such as obesity 
(>7% increase in weight), glucose abnormalities (i.e., hyperglycemia), dyslipidemia, and 
metabolic syndrome.16 This is of concern as studies have shown that an increase in weight during 
childhood is a determinant of cardiovascular risk.17 Weight has a direct correlation with 
cardiovascular disease. Childhood BMI, weight, and height were significantly correlated with 
increase in weight, BMI, height, insulin and lipid levels, and systolic blood pressure during 
adulthood.17 Other studies showed that higher BMI during childhood was associated with 
increased fatal heart diseases as adults.17,18 Childhood obesity is also a predictor of adulthood 
obesity and diabetes,19 which are both risk factors for the development of type 2 diabetes mellitus 
and hyperlipidemia during childhood.15
 B. Objective and Specific Aims 
 However the prevalence of anti-diabetic and 
antilipidemic medication use among children and adolescents using atypical antipsychotics has 
not been characterized.  
The objective of this study was to determine if the prevalence of anti-diabetic and antilipidemic 
medication use among children and adolescents treated with atypical antipsychotics is higher 
than the prevalence among children and adolescents not treated with atypical antipsychotics. 
Another goal of the study was to determine the odds of receiving an anti-diabetic or 
antilipidemic medication based on individual atypical antipsychotic therapy.  
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This study had the following specific aims: 
Specific Aim IA:  
To determine and compare the prevalence of anti-diabetic medication use in children and 
adolescents treated with atypical antipsychotics to those not treated with atypical antipsychotics. 
Specific Aim IB:  
To determine and compare the prevalence of antilipidemic medication use in children and 
adolescents treated with atypical antipsychotics to those not treated with atypical antipsychotics. 
Specific Aim IIA:  
To examine the relationship between the use of individual atypical antipsychotic agents and use 
of anti-diabetic medication in children and adolescents.  
Specific Aim IIB:  
To examine the relationship between the use of individual atypical antipsychotic agents and use 
of antilipidemic medication in children and adolescents.  
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C. Significance 
The metabolic adverse effects of atypical antipsychotics have become problematic among 
children and adolescents. Increased weight gain and other metabolic effects are usually 
precursors to the development of diabetes and hyperlipidemia. There are studies in the adult 
population that observed the development of type 2 diabetes or hyperlipidemia after initiation of 
antipsychotic treatment.12, 13 There is a similar study by Andrade et al. that evaluated the risk of 
development of type 2 diabetes mellitus in children and adolescents.20
 
 Our trial is innovative 
because no study to date has directly investigated the prevalence of anti-diabetic and 
antilipidemic medication use in children and adolescents less than 17 years of age treated with 
atypical antipsychotic agents. There are also no published data on the association between each 
atypical agent and the use of anti-diabetic or antilipidemic medications. The main objectives of 
our study were to determine the prevalence of anti-diabetic and antilipidemic medication use 
among children and adolescents receiving atypical antipsychotics, and to evaluate whether the 
prevalence of anti-diabetic and lipid lowering medication use differs among the atypical 
antipsychotic agents. Documenting the odds of receiving an anti-diabetic or antilipidemic 
medication based on individual atypical agent can help clinicians make informed decisions 
regarding drug selection among the various atypical antipsychotics. It will help clinicians decide 
which atypical agents have the least amount of risk, and should be considered for children and 
adolescents, and which of these agents should be avoided if possible.  
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Chapter 2: Literature Review 
A. Antipsychotic Medication Prescribing Trend 
Studies that involved children enrolled in Medicaid programs and Health Maintenance 
organizations (HMO) have shown that there is a significant increase in the use of 
antipsychotics.21-23 The study by Patel et al. showed that antipsychotic use was prominent among 
10- to 19-year-olds but the greatest increase in use was seen among 5- to 9-year-olds.23 The study 
by Cooper et al. reported that during 1995 to 2002, there were 5,762,193 outpatients visits, 
during which an antipsychotic was prescribed, by children in the United States less than 18 years 
of age. Two-thirds of these children were male and the mean age was 12.9 years. The frequency 
of antipsychotic prescriptions for children had increased from 8.6 per 1000 children in 1995-
1996 to 39.4 per 1000 children in 2001-2002.21 A very recent study by Zito et al. showed that the 
overall prevalence of antipsychotic use increased from 1.2% in 1997 to 3.2% in 2006.
B. Metabolic Adverse Effects of Atypical Antipsychotics  
24 
As stated in the previous chapter, the majority of the antipsychotic prescriptions for children and 
adolescents are for atypical antipsychotics since these agents are associated with lower risk of 
EPS. Although atypical agents have lower propensity to cause EPS, there is an increasing 
concern about whether these agents induce serous metabolic adverse effects (i.e., weight gain, 
hyperglycemia and hyperlipidemia). A review by Newcomer showed that atypical antipsychotics 
are associated with increased weight gain, decreased insulin sensitivity, and changes in lipid 
profiles thus increasing the risk of patients to develop type 2 diabetes mellitus, hyperlipidemia, 
and metabolic syndrome.25 Metabolic syndrome is common in obese patients and predisposes 
children to atherosclerotic cardiovascular disease.26 
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Weight: It has been shown that use of atypical antipsychotics has been associated with increased 
weight gain. Olanzapine and risperidone were commonly studied antipsychotics and though both 
cause increased weight gain, olanzapine seems to be associated with significantly greater weight 
gain. One of the largest cohort studies conducted in a pediatric population of first-time atypical 
antipsychotic users showed that olanzapine caused a mean increase of 8.5 kg (95% confidence 
interval [CI] = 7.4 - 9.7 kg) after a median of 10.8 weeks. The study looked at a wide array of 
antipsychotics and all caused varying degrees of weight gain in order of olanzapine> quetiapine> 
risperidone> aripiprazole. They also had a comparison untreated group which had minimal 
weight change of 0.2 kg (95% CI = -1.0 - 1.4 kg) within the same time frame.16
Another study showed that during the course of treatment (27 days), 7 new cases or 28% within 
the olanzapine group and 4 new cases or 17% within the risperidone group were overweight or at 
risk of being overweight with a BMI> 85%.
   
27 Another longitudinal study showed that even 
though there was a significant increase in the BMI z score in the olanzapine and risperidone 
groups (p<0.05), there was no significant weight gain in the quetiapine group. At the end of the 
6-month, follow-up period 33% of the patients had significant weight gain, irrespective of 
group.
The study by McIntyre et al. showed that the odds of excessive weight gain were significantly 
higher for girls and adolescents aged 13 years or older compared with boys. The mean age 
(standard deviation [SD]) at the onset of obesity was found to be 13.3 (3.7) years in this study.
28 
The study by Moreno et al. compared weight gain among young patients with bipolar disorder 
(psychotic and non-psychotic) who were prescribed atypical antipsychotics. Results showed that 
there was a gain of about 5.5 kg after the 3-month follow-up in the sample as a whole and no 
29 
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significant differences were found in weight gain among patients with psychotic or non-
psychotic disorders.
Hyperglycemia: In a large cohort study, olanzapine was associated with the greatest increase in 
glucose levels (3.14 mg/dL, 95% CI = 0.69 - 5.59, p-value < 0.05). Following olanzapine was 
quetiapine, with moderately higher rates of hyperglycemia even though statistical significance 
was not acheived.
30 
16 The study by Fraguas et al. did not show any statistically significant increase 
in the glucose levels among the various atypical antipsychotics.28 This was similar to the results 
of other longitudinal studies. Changes in fasting glucose did not reach statistical 
significance.
One study showed that girls were at an increased risk of developing diabetes mellitus (odds ratio 
[OR] = 1.79, 95% CI = 1.28 – 2.50) compared with boys. Similarly adolescents over 13 years of 
age and those who were exposed to multiple antipsychotics were at an increased risk of 
developing diabetes mellitus compared with younger children. The mean (SD) at the onset for 
incident type 2 diabetes mellitus was 13.8 (3.8) years.
27,30-32 
A possible mechanism could include antagonism of the serotonin 5-HT
29 
1A/2A/2C receptors, which 
results in the inhibition of insulin release, insulin resistance, or impaired glucose utilization. The 
effects of atypical antipsychotics on alpha adrenergic receptors could also affect the pancreatic 
beta cell function.
Hyperlipidemia: A large cohort study showed that olanzapine and quetiapine had a statistically 
significant baseline-to-endpoint change in total cholesterol, triglycerides, and non-HDL. The 
levels of triglycerides with risperidone were raised significantly. Total cholesterol levels 
increased by 15.58 mg/dL (95% CI = 6.88 - 24.28) and 9.05 mg/dL (95% CI = 0.41 - 17.69) 
33 
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within the olanzapine and quetiapine groups, respectively. Triglycerides levels increased by 
almost 37 mg/dL in the quetiapine group.
A smaller cohort of 66 children also showed that total cholesterol levels had significantly 
increased in the group of patients who had received olanzapine (p-value = 0.047) and quetiapine 
(p-value = 0.016) but no significant changes were observed in the risperidone group.
16 
28
Interestingly, another cohort showed that the rate of dyslipidemia was higher in girls than among 
boys (OR = 2.08, 95% CI = 1.41 - 3.03) and among those who received more than one 
antipsychotic. The study also showed that the risk of patients with preexisting obesity and 
hypertension developing dyslipidemia was almost 4.5 times greater if they had taken an 
antipsychotic than if they were antipsychotic-naive.
  
29 Another longitudinal study showed that 
patients with bipolar disorder and other psychotic disorders had significant increase in 
cholesterol levels at the end of three months while HDL and triglycerides did not change within 
any group.
One of the smaller studies in children with Tourette’s disorder showed similar results. Thirty-
three of the total seventy-three children had developed lipid abnormalities over the 
30  
  course of the 
study, 28 of the 33 had elevated low density lipoproteins (LDL) values, 8 had decreased HDL 
values, and some others had elevated triglyceride values.31 In the study by Khan et al., fasting 
lipid profiles were obtained for 72% of the 25 patients in the olanzapine group and for 75% of 
the 24 patients receiving risperidone. In the olanzapine group, four of the patients had 
triglyceride levels equal to or exceeding 110 mg/dL with one patient exceeding 250 mg/dL. 
Similarly in the risperidone group, only one out of the 18 patients had triglyceride levels equal to 
or exceeding 250 mg/dL.27 
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Other Outcomes: Some of the studies also reported other outcomes that could be potentially 
related to metabolic disturbances. Fraguas et al. showed that quetiapine was associated with a 
statistically significant decrease in free thyroxine (FT4),28 and the systolic blood pressure among 
patients taking olanzapine was higher than other antipsychotic groups.27,28 Moreno et al. 
concluded that patients receiving second generation antipsychotics, especially higher doses, were 
vulnerable to adverse health outcomes (i.e., decrease in FT4, increase in thyroid stimulating 
hormone [TSH]).
C. Risk of Metabolic Adverse Effects between Atypical Agents 
30  
Adult studies 
A study was conducted by Lambert et al. to evaluate the association between antipsychotic 
treatment and type 2 diabetes in adult patients with a diagnosis of schizophrenia. It was a 
matched case-control study design conducted on California Medicaid beneficiaries. Patients with 
type 2 diabetes were identified using diagnosis codes and receipt of an anti-diabetic medication. 
Their results showed that the odds of developing type 2 diabetes were significantly higher in 
patients treated with olanzapine than in patients treated with risperidone. The study concluded 
that certain atypical antipsychotics (i.e., olanzapine and clozapine) are associated with 
significantly increased risk of developing new onset diabetes.
Another similar study by Lambert et al. looked at the association between antipsychotic 
treatment and hyperlipidemia in patients with schizophrenia. The study concluded that the risk of 
developing hyperlipidemia was higher among olanzapine users compared to other atypical 
antipsychotics.
34  
35 The study reported that patients who had developed hyperlipidemia were more 
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likely to have been exposed to olanzapine (OR = 1.20, 95% CI = 1.08-1.33). Exposure to 
risperidone and quetiapine were not significantly associated with developing hyperlipidemia.
Pediatric Studies 
35 
Table 2.1 shows the studies that have compared some of the atypical antipsychotics and their 
propensity to cause metabolic adverse effects in children and adolescents. Except for one study 
there were no significant changes in the blood glucose levels. Correll et al. reported that 
olanzapine users did have a significant increase in their blood glucose levels.
 All the studies showed that olanzapine users had the highest weight gain when compared with 
other antipsychotics. Quetiapine and risperidone users did have some weight gain. Since obesity 
and weight gain are predictors for insulin resistance and glucose insensitivity, olanzapine users 
may be pre-disposed to developing diabetes mellitus.   
16 
All the studies showed that children and adolescents using olanzapine had the highest increase in 
triglycerides and total cholesterol levels in comparison with other psychotics. None of the studies 
showed risperidone to have any significant effect on lipid levels.  
The studies seem to indicate that olanzapine users have the highest risk of developing metabolic 
adverse effects (e.g., hyperlipidemia and hyperglycemia).  
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Table 2.1: Review of studies  
Reference 
(year) Drugs Studied Glucose Lipids Weight Gain 
Correll et al. 
(2009)
A= Aripiprazole 
16 
  O= Olanzapine 
  Q= Quetiapine 
R= Risperidone 
 
O:  significant 
increase by 3.14 
mg/dL  
O: significant increase in 
triglycerides, LDL and 
total cholesterol 
 
R,Q: significant increase 
in triglyceride 
O  (8.5 kg) > Q (6.1 kg) > R 
(5.3 kg) 
Fraguas et 
al. (2008)
R= Risperidone 
28   O= Olanzapine   Q= Quetiapine 
No significant 
increase 
O: 10 mg/dL increase in 
total cholesterol 
O (11 kg) > R (5 kg) > Q 
(2.5 kg). 
Khan et al. 
(2009)
O= Olanzapine 
27  R= Risperidone 
No significant 
changes in fasting 
glucose 
O: 4 patients with 
elevated triglycerides 
O: BMI increase by1.7 
kg/m
 
2 
R: BM increase by 1.3 
kg/m2 
Sikich et al. 
(2008)
O= Olanzapine 
32 
 R= Risperidone 
 
 
No significant 
changes in glucose 
profile 
O: significant increase in 
total cholesterol (19.9 
mg/dL) and LDL (14.7 
mg/dL) 
O: significant increase in 
weight (6.1 kg) 
 
R: increase of 3.6 kg 
 
 
D. Type 2 Diabetes Mellitus in Children and Adolescents 
 Type 2 diabetes is characterized by insulin resistance and a decrease in insulin secretion. In 
children, it may lead to the early onset of cardiovascular disease, retinopathy, nephropathy, and 
neuropathy if uncontrolled.36 Other chronic complications include end-stage renal disease and 
limb amputations. Because of these complications there is early morbidity and mortality among 
diabetic patients.37 Type 2 diabetes is associated with other insulin resistant features (e.g., 
hyperlipidemia, hypertension and non-alcoholic fatty liver disease).38 In youth, the mean age of 
onset is usually around 13.5 years and there is a greater prevalence among patients with non-
white European descent.
 
39 
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Diagnostic criteria for type 2 diabetes in children and adolescents (any one of the three):
1)  A fasting plasma glucose ≥ 126 mg/dL 
39 
2) The post challenge plasma glucose is > 200 mg/dL 
3) Symptoms (polyuria, polydypsia, blurring of vision, and weight loss) of diabetes and a 
casual plasma glucose ≥ 200 mg/dL 
The treatment of type 2 diabetes in children and adolescents is multifaceted. Non-pharmacologic 
therapy (e.g., diet, exercise, and lifestyle modifications) is encouraged before pharmacologic 
therapy is initiated. The first-line of therapy is metformin. It has similar HbA1c reducing 
properties to sulfonylureas with minimal risk of hypoglycemia. Metformin can also help with 
decreasing weight. Metformin is approved for pediatric use and other treatment options should 
be initiated only after failure of monotherapy with metformin.
E. Hyperlipidemia in Children and Adolescents  
39 
Cardiovascular disease is one of the leading causes of death in the United States. A clinical 
report by Daniels et al. reports that even though the clinical burden of CVD occurs in adulthood, 
the process of atherosclerotic CVD starts earlier on in life during childhood years.40 A clinical 
trial found that 15.6% of girls and 11.1% of boys had total cholesterol concentrations greater 
than 200 mg/dL.41
Ford et al. reported that only 0.8% of US teens had a LDL cholesterol level above the 
recommended threshold level (>190 mg/dL or > 160 mg/dL with risk factors) requiring 
pharmacotherapy. On the other hand, the study also reported that elevated cholesterol levels were 
found to affect 9-10% of US teens.
  
42 
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According to the latest National Cholesterol Education Program (NCEP) guidelines, the 
following cut offs should be used to diagnose abnormal cholesterol concentrations in children 
and adolescents:
1) Total cholesterol < 170 mg/dL and LDL < 110 mg/dL is acceptable 
 43 
2) Total cholesterol 170-199 mg/dL and LDL 110-129 mg/dL is borderline 
3) Total cholesterol ≥ 200 mg/dL and LDL ≥ 130 mg/dL is elevated 
The NCEP does not recommend routine lipid screening for children 2-8 years of age and 
adolescents 12-16 years of age unless they have diabetes, hypertension, increased BMI (≥ 95th 
percentile for children and ≥ 85 th percentile for adolescents), history of smoking, a strong family 
history of CVD, or a parent with total cholesterol greater than or equal to 240 mg/dL.43 For 
children 9-11 years of age NCEP does recommend universal screening with a fasting lipid 
panel.43 
According to the guidelines, hyperlipidemia should be initially treated using non-pharmacologic 
therapy (i.e., healthy lifestyle, dietary modifications). Dietary changes which focus on reducing 
calorie intake from total and saturated fat are recommended (except for children younger than 2 
years). Pharmacologic therapy is reserved only for children greater than or equal to 10 years old 
with a LDL ≥ 190 mg/dL  with no other risk factors, or ≥ 160 mg/dL with risk factors. Children 
younger than 10 years should not receive pharmacologic therapy unless they have severe primary 
hyperlipidemia or have a dramatic elevation in LDL ≥ 400 mg/dL or triglycerides  ≥ 500 mg/dL. 
If pharmacologic therapy is warranted, statin therapy should be considered.
  
43 Statin therapies 
have been shown to be safe and effective in children.44 The lowest available dose should be given 
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once daily and children taking statins should have routine monitoring for adverse effects related 
to muscle toxicity.
F. Gaps in Literature 
43 
It is known that atypical antipsychotics can cause metabolic adverse effects in adults45 and a 
study by Draeger et al. has reported the prevalence of anti-diabetic and antilipidemic medication 
use among antipsychotic users in an adult population.46 Studies in the pediatric population have 
shown that atypical antipsychotics have the propensity to cause metabolic adverse effects (e.g., 
weight gain, dyslipidemia and insulin resistance).
No study has looked directly at the prevalence of anti-diabetic and antilipidemic medication use 
among children and adolescents exposed to atypical antipsychotics. There is knowledge that 
atypical antipsychotics can cause type 2 diabetes and hyperlipidemia but there is no information 
about how many of these children are prescribed medications for these metabolic conditions.  
16,27,28,32 
Additionally, there are not studies that report the odds of receiving an anti-diabetic or 
antilipidemic medication among the various atypical antipsychotic agents. This information 
could help clinicians make informed decisions about which of the atypical antipsychotics is the 
safest to prescribe. 
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Chapter 3: Methodology 
A. Study Design and Data Source 
This was a cross-sectional study using the Virginia Medicaid pharmacy claims data. The dataset 
was obtained from the Department of Medical Assistance Services (DMAS), the agency that 
administers Medicaid and CHIP (Children’s Health Insurance Program). Medicaid is the health 
program that is targeted to help families with low income and people with certain disabilities.  
For the purpose of this study, Medicaid was an ideal source of data because medication 
information on children and adolescents could be obtained. All patient identifiers were removed 
by DMAS to protect the privacy of the patient. Each subject was assigned a unique identifier 
number by DMAS that was used to link the subject across files.  
The study was approved by the Virginia Commonwealth University Institutional Review Board, 
Office of Research Subjects Protection in February 2012.  
B. Study Population 
Virginia Medicaid beneficiaries were included in the study if they met the following inclusion 
criteria: 
(i) Subjects were between 2 and 17 years of age. 
(ii) Subjects were continuously enrolled in the Medicaid system (Fee-For-Service and Managed 
Care) from July 31, 2010 to August 1, 2011. 
(iii) Only subjects with at least two paid prescription claims for the atypical antipsychotics 
aripiprazole, quetiapine, olanzapine, risperidone, or ziprasidone were included to be in the 
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exposed group. The newer antipsychotic agents (i.e., lurasidone, paliperidone, iloperidone, 
asenapine) were not included in the study as substantial use of these atypical antipsychotic agents 
in the pediatric population had not been reported. 
Subjects were excluded if they met any of the following criteria: 
(i) They had juvenile diabetes identified using ICD-9-CM code 250.x1 or 250.x3. 
(ii) They had paid pharmacy claims for a typical antipsychotic (e.g., haloperidol, thiothixene, 
chlorpromazine, fluphenazine, and perphenazine).  
(iii) They had paid claims for more than one atypical antipsychotic during the study period. 
Subjects using more than one antipsychotic during the study period were excluded so that the 
prevalence of the outcome could be attributed to the particular antipsychotic agent being studied. 
C. Data Collection 
After excluding subjects with ICD-9-CM codes for juvenile diabetes and those who had 
pharmacy claims for typical antipsychotics, two data files were obtained from DMAS. The 
exposed file included all the subjects who had paid pharmacy claims for atypical antipsychotics 
during the study period. The file also included all other paid pharmacy claims the subjects had 
during the year. The unexposed file included all subjects who had any pharmacy claims during 
the study period but were not included in the first file.  
Variables: Both files contained the following variables: 
- Unique patient identifier: Each subject was assigned a unique 7-digit number. 
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- Drug name and strength: Each claim was accompanied by the name of the drug and the 
strength. Each drug was identified using the Generic Code Number (GCN) which groups drugs 
with the same ingredients, strength, dosage form, and route of administration.  
- Age: Age of the subjects was provided as a continuous variable measured in years. Categorical 
variables for age were created. Subjects were divided into three categories: 2-4 years, 5-11 years, 
and 12-17 years of age. The categories were based on the age categorization used by the Centers 
for Disease Control and Prevention (CDC) which approximates pre-schoolers, middle childhood, 
and teenagers.47
- Sex: Sex of the subjects was provided and treated as the categorical variables males and 
females. 
  
- Race: This categorical variable included White, African-American, American Indian, 
Oriental/Asian, Hispanic, Native Hawaiian, Asian and White, African-American and White, 
Unknown, Asian and African-American, and Other. The classes were collapsed into White, 
African-American, and Others because of the smaller number of subjects among the other 
groups.  
D. Specific Aim I 
Identification of Groups 
Unexposed group: From the unexposed file given by DMAS, only subjects who were 
continuously enrolled in Medicaid during the study period were included. These subjects 
composed the unexposed group. The demographic variables age, sex, and race were reported for 
the unexposed subjects.  
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Exposed group: From the exposed file, only subjects who were continuously enrolled during the 
study period and had at least two paid prescription claims for atypical antipsychotics were 
included. All subjects who had prescription claims for more than one atypical antipsychotic were 
excluded from this group. The remaining subjects comprised the exposed group. The 
demographic variables age, sex, and race were reported for all exposed subjects.  
Specific Aim IA: To determine and compare the prevalence of anti-diabetic medication use 
in children and adolescents treated with atypical antipsychotics to those not treated with 
atypical antipsychotics. 
Outcome: In the unexposed and exposed groups, subjects using anti-diabetic medications were 
identified from the pharmacy claims data using the GCN. The anti-diabetic agents included 
insulin, glimepiride, glyburide, glipizide, metformin, glipizide/metformin, glyburide/metformin, 
pioglitazone, pioglitazone/metformin, rosiglitazone, sitagliptin, acarbose, exenatide, and 
liraglutide. Subjects who had a prescription claim for an anti-diabetic medication were assigned 
outcome = 1 and other subjects without a prescription claim were assigned outcome = 0 . 
Demographic variables age, sex, and race were reported for all subjects in each group who had 
an anti-diabetic pharmacy claim. The prevalence of use of anti-diabetic medications was then 
computed in the unexposed and exposed groups:  
 
Prevalence= 
                  Total number of subjects in unexposed group 
Number of subjects with claims for anti-diabetic medication in unexposed group 
 
Prevalence= Number of subjects with claims for anti-diabetic medication in exposed group
                  Total number of subjects in exposed group 
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Specific Aim IB: To determine and compare the prevalence of antilipidemic medication use 
in children and adolescents treated with atypical antipsychotics to those not treated with 
atypical antipsychotics. 
Outcome: In the unexposed and exposed groups, subjects using antilipidemic medications were 
identified from the pharmacy claims data using the GCN. The antilipidemic agents included 
atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, cholestyramine, colestipol, niacin, 
ezetimibe, fenofibrate, and gemfibrozil. Subjects who had a prescription claim for an 
antilipidemic medication were assigned outcome = 1 and subjects without a prescription claim 
for an antilipidemic medication were assigned outcome = 0. Demographic variables age, sex, and 
race were reported for all subjects in each group who had an antilipidemic pharmacy claim. The 
prevalence of use of antilipidemic medications was then computed in the unexposed and exposed 
groups:  
 
Prevalence= Number of subjects with claims for antilipidemic medication in unexposed group
                  Total number of subjects in unexposed group 
  
 
Prevalence= Number of subjects with claims for antilipidemic medication in exposed group
                  Total number of subjects in exposed group 
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E. Specific Aim II 
Identification of Subgroups 
Subjects who were identified as the exposed group in Specific Aim I were further classified into 
five subgroups based on the atypical antipsychotic agent they received. The subgroups were 
aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone users. The medications were 
identified using the GCN. The demographics of the subjects receiving each atypical 
antipsychotic subgroup were reported.  
Specific Aim IIA: To examine the relationship between the use of individual atypical 
antipsychotic agents and use of anti-diabetic medication in children and adolescents.  
Outcome: Within the five antipsychotic subgroups, subjects using anti-diabetic medications were 
identified from the pharmacy claims data. Subjects who had a prescription claim for an anti-
diabetic medication were assigned outcome = 1 and subjects without an anti-diabetic pharmacy 
claim were assigned outcome = 0. The prevalence of use of anti-diabetic medications within each 
atypical antipsychotic subgroup was computed:  
 
 Prevalence= Number of subjects with prescription claims for anti-diabetic medication
                   Total number of subjects using atypical antipsychotic X 
  
 
 X = aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone 
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Specific Aim IIB: To examine the relationship between the use of individual atypical 
antipsychotic agents and use of antilipidemic medication in children and adolescents.  
Outcome: Within the five subgroups, subjects using antilipidemic medications were identified 
from the pharmacy claims data. Subjects who had a prescription claim for an antilipidemic 
medication were assigned outcome = 1 and subjects without an antilipidemic medication 
pharmacy claim were assigned outcome = 0. The prevalence of use of antilipidemic agents by 
subjects within each atypical antipsychotic subgroup was computed:  
 
 Prevalence= Number of subjects with prescription claims for antilipidemic medication
                   Total number of subjects using atypical antipsychotic X 
  
 
 X = aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone 
 
  
F. Statistical Analyses 
Descriptive statistics were used to summarize the demographic variables age, sex, and race. 
Categorical data was described using percents and counts. Normal continuous data were 
described using mean and standard deviation. Chi-square test of homogeneity was performed to 
test for differences between age, sex, and race between the exposed and the unexposed groups. 
Fisher’s exact test was used when there was inadequate cell size. The prevalence of outcomes 
between unexposed and exposed groups was compared using Chi-square test of independence. 
For the second specific aim, the number and percentage of subjects using each of the atypical 
antipsychotics was reported.  
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Logistic regression analyses were used to test the following: 
Specific Aim IA: The relationship between exposure to atypical antipsychotics (Yes = exposed 
group, No = unexposed group) and outcome (1 = anti-diabetic claim, 0 = no anti-diabetic claim).  
Specific Aim IB: The relationship between exposure to atypical antipsychotics (Yes = exposed 
group, No = unexposed group) and outcome (1 = antilipidemic claim, 0 = no antilipidemic 
claim).  
Specific Aim IIA: The relationship between exposure to individual atypical antipsychotic agent 
(aripiprazole = 1, olanzapine = 2, quetiapine = 3, risperidone = 4, ziprasidone = 5) and outcome 
(1 = anti-diabetic claim, 0 = no anti-diabetic claim).  
Specific Aim IIB: The relationship between exposure to individual atypical antipsychotic agent 
(aripiprazole = 1, olanzapine = 2, quetiapine = 3, risperidone = 4, ziprasidone = 5) and outcome 
(1 = antilipidemic claim, 0 = no antilipidemic claim).   
In the first specific aim, the unexposed group was used as the reference. For the second specific 
aim, olanzapine was used as the reference. Since olanzapine had the highest propensity to cause 
weight gain, dyslipidemia and glucose imbalance, it was chosen as the reference.16, 27, 30, 32 
Logistic regression analyses were performed. Logistic regression analyses, controlled for age, 
sex, and/or race, were also performed if the variables were found to have a significant 
relationship with the outcome individually. The unadjusted and adjusted OR and 95% confidence 
intervals were reported for all logistic regression analyses. For the adjusted OR, 2-4 years, male, 
and White were used as the reference groups for age, sex, and race respectively. All tests were 
performed at a significance level of 0.05, and SAS 9.3 statistical package was used for all 
analyses. 
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Chapter 4: RESULTS 
A. Comparison of Subjects Exposed and Unexposed to Atypical Antipsychotics 
DMAS provided two files after excluding subjects with a diagnosis of juvenile diabetes and 
subjects with pharmacy claims for typical antipsychotics. One file was for the unexposed group 
and the other for the exposed group. The unexposed file contained information on 2,502,643 
pharmacy claims. After including only those subjects who were continuously enrolled in the 
Virginia Medicaid system during the study period, a total of 299,593 unique subjects with 
2,286,629 claims were identified in the unexposed group. 
The second file had information on the subjects who were exposed to atypical antipsychotics. It 
contained information on 438,124 pharmacy claims. As shown in Figure 4.1, 244,283 claims 
remained after including only subjects with one year of continuous enrollment. After including 
only those subjects who had at least 2 paid pharmacy claims per atypical antipsychotic, 53,236 
claims remained. A total of 4,922 unique subjects were identified in the exposed group after 
excluding for subjects receiving more than one atypical antipsychotic.  
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Figure 4.1: Flow of claims after application of inclusion/exclusion criteria 
 
 
(i) Baseline Characteristics of the Study Groups 
Unexposed group: Table 4.1 illustrates the baseline demographic characteristics of the subjects 
by exposure to atypical antipsychotics. The mean age (SD) of the total sample of unexposed 
children was 8.23 (4.70) years with the highest percentage of children (43.34%) falling within 
the category of 5- to 11-year-olds. Approximately 38% of the subjects were White and African-
American each and there was an equal distribution of males versus females.  
Exposed group: Baseline characteristics of the subjects in the exposed group are shown in Table 
4.1. The mean age of the subjects was 11.77 (3.65) years and almost 55% of the subjects were 
between 12 and 17 years of age. More than two-thirds of the subjects were male and the majority 
was White.  
Total number of patients after excluding patients with polypharmacy of atypical antipsychotics 
4,922 
Total number of claims after inlcuding only subjects with at least 2 paid claims for the atypical 
antipsychotic of interest 
53,236 
Total number of claims after including only subjects with one year of continuous enrollment  
244,183 
Total number of claims after excluding for juvenile diabetes and claims for typical antipsychotics 
438,124 
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The unexposed and exposed groups were significantly different in their baseline demographics 
(Table 4.1). Therefore, age, sex, and race was controlled for in the logistic regression analyses.  
Table 4.1: Baseline demographic characteristics of study subjects 
Characteristic 
Unexposed Group  
n (%) 
(N=299,593) 
Exposed Group  
n (%) 
(N=4,922) 
p-value 
Age:   2-4 years 
           5-11 years 
           12-17 years 
           Mean (SD) 
86,362 (28.83) 
129,838 (43.34) 
83,393 (27.84) 
8.23 (4.70) 
113 (2.3) 
2,088 (42.42) 
2,721 (55.28) 
11.77 (3.65) 
<0.0001 
Sex:    Males 150,059 (50.09) 3,367 (68.41) <0.0001 
Race: White 
           African-American 
           Others 
115,011 (38.39) 
113,671 (37.94) 
70,911 (23.67) 
3,261 (66.25) 
1,187 (24.12) 
474 (9.63) 
<0.0001 
 
(ii) Prevalence of Anti-diabetic Medication Use  
In the unexposed group, 957 of 299,593 subjects had paid claims for an anti-diabetic medication 
during the study period. In the exposed group, 69 of 4,922 subjects had paid claims for an anti-
diabetic medication. The prevalence of anti-diabetic medication claims was 0.32% among 
children and adolescents who were not exposed to antipsychotics and 1.40% in those exposed to 
atypical antipsychotics. The prevalence of anti-diabetic medication use was significantly higher 
among the subjects exposed to atypical antipsychotics compared with those who were not 
exposed (χ2 = 168.96, df = 1, p-value < 0.0001). Demographics of subjects on anti-diabetic 
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medications are shown in Table 4.2. Because of the small cell sizes, Fisher’s exact test was 
performed. Sex and race were found to be significantly different between the two groups. There 
were significantly more males in the exposed group who had claims for anti-diabetic 
medications. There was no significant difference in the ages between the groups (p-value = 
0.3667). Of the subjects with claims for antidiabetic drugs, 92.75% in the exposed and 83.70% in 
the unexposed group had claims for metformin.  
Table 4.2: Demographics of subjects with claims for anti-diabetic medications 
Characteristic 
Anti-diabetic claims 
p-value Unexposed 
Group 
n (%) 
(N=957) 
Exposed 
Group 
n (%) 
(N=69) 
Age:   2-4 years 
 
           5-11 years 
 
           12-17 years 
 
            Mean (SD) 
4 (0.42) 
 
175 (18.29) 
 
778 (81.30) 
 
13.82 (2.67) 
1 (1.45) 
 
13 (18.84) 
 
55 (79.71) 
 
13.86 (2.92) 
0.3667 
Sex:    Males  272 (28.42) 30 (43.48) 0.0131 
Race:  White  
           African-American 
           Others  
445 (46.50) 
399 (41.69) 
113 (11.81) 
49 (71.01) 
18 (26.09) 
2 (2.90) 
<0.0001 
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Logistic regression analyses: In the regression analysis, exposure to an atypical antipsychotic 
was found to be an important predictor to whether a subject received an anti-diabetic medication     
(χ2 = 141.08, df = 1, p-value < 0.0001). The odds of having a claim for anti-diabetic medication 
for children and adolescents exposed to an atypical antipsychotic agent were 4.44 (95% CI = 
3.47 - 5.68) times higher than in children and adolescents not exposed to these agents. Age (χ2 = 
679.04, df = 2, p-value < 0.0001), sex (χ2 = 169.29, df = 1, p-value < 0.0001), and race (χ2 
 
= 
85.32, df = 2, p-value < 0.0001) were found to have a significant relationship with receiving an 
anti-diabetic medication. Table 4.3 summarizes the results of the unadjusted and adjusted logistic 
regression analyses. After controlling for age, sex, and race the odds of having a claim for anti-
diabetic medication for children and adolescents exposed to an atypical antipsychotic agent were 
2.76 (95% CI = 2.15 - 3.55, p-value < 0.0001) times higher than children and adolescents not 
exposed to antipsychotics. Children between 5 and 17 years had higher odds of having anti-
diabetic medications compared with 2- to 4-year-olds. Female children were at higher odds of 
being prescribed an anti-diabetic medication. White children had higher odds of anti-diabetic 
medication use compared with African American children or those of other race.  
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Table 4.3: Regression analyses for prevalence of anti-diabetic medications  
 Unadjusted Regression Model 
Adjusted Regression Model 
controlling for Age, Sex, and Race 
 OR 
95% CI 
OR 
95% CI 
Lower Upper Lower Upper 
Exposure       
Unexposed 1 (reference)   1 (reference)   
Exposed 4.44 3.47 5.68 2.76 2.15 3.55 
Age 
2-4 years 
5-11 years 
12-17 years 
N/A    
1 (reference) 
23.23 
146.09 
 
 
9.56 
60.62 
 
 
56.47 
352.05 
Sex N/A      
Male    1 (reference)   
Female    2.34 2.04 2.67 
Race N/A      
White    1 (reference)   
African-American    0.91 0.79 1.03 
Others    0.61 0.50 0.75 
 
(iii) Prevalence of Antilipidemic Medication Use  
In the unexposed group, 261 of the 299,593 subjects had paid claims for an antilipidemic 
medication during the year. Within the exposed group, 17 of the 4,922 subjects had paid claims 
for an antilipidemic medication. The prevalence of antilipidemic medication use among children 
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and adolescents who were not exposed to antipsychotics was 0.09% which was significantly 
lower than the 0.35% prevalence of antilipidemic medication use in those exposed to atypical 
antipsychotics (χ2 
Table 4.4: Demographics of subjects with claims for antilipidemic medications 
= 35.41, df = 1, p-value < 0.0001). Demographics of subjects on antilipidemic 
medication use are listed in Table 4.4. Fisher’s exact test showed that sex and race were 
significantly different between the two groups. In the exposed group, significantly more males 
had claims for antilipidemic medications (p-value = 0.0416). There was no significant difference 
in the ages between the groups (p-value = 0.2909). A total of 64.71% of the subjects in the 
exposed and 55.17% subjects in the unexposed group had claims for statins.  
Characteristic 
Antilipidemic claims 
p-value Unexposed 
Group 
n (%) 
(N=261) 
Exposed  
Group 
n (%) 
(N=17) 
Age:   2-4 years 
           5-11 years 
           12-17 years 
            Mean (SD) 
37 (14.18) 
58 (22.22) 
166 (63.60) 
11.82 (4.93) 
0 
4 (23.53) 
13 (76.47) 
13.94 (3.75) 
0.2909* 
Sex:    Males  146 (55.94) 14 (82.36) 0.0416 
Race: White  
           African-American  
           Others  
142 (54.41) 
61 (23.37) 
58 (22.22) 
14 (82.35) 
3 (17.65) 
0 
0.0326 
*Non-significant 
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Logistic regression analyses: In the regression analysis exposure to an atypical antipsychotic was 
found to be an important predictor to whether a subject received an antilipidemic medication    
(χ2 = 30.30, df = 1, p-value < 0.0001). The odds of having a claim for an antilipidemic 
medication for children and adolescents exposed to the atypical antipsychotic agent were 3.97 
(95% CI = 2.43 - 6.50) times higher than children and adolescents not exposed to antipsychotics. 
Age (χ2 = 148.01, df = 2, p-value < 0.0001), sex (χ2 = 5.68, df = 1, p-value < 0.0171) and race 
(χ2
 
=36.24, df = 2, p-value < 0.0001) were found to have a significant association with whether 
the subjects received an antilipidemic medication. Table 4.5 shows the results of the adjusted and 
unadjusted logistic regression analyses. When controlled for age, sex, and race the odds of 
having a claim for an antilipidemic medication for children and adolescents exposed to an 
atypical antipsychotic agent were 2.12 (95% CI = 1.34 - 3.64, p-value = 0.0018) higher than 
children and adolescents not exposed to these agents. Subjects 12 to 17 years of age were found 
to have higher odds than 2- to 4-year-olds to receive antilipidemic medications. Unlike the 
results with anti-diabetic medications, females were found to have lower odds than males to 
receive an antilipidemic medication. White children had higher odds than African-American 
children of having antilipidemic medication claims. 
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Table 4.5: Regression analyses for prevalence of antilipidemic medications  
 Unadjusted Regression Model 
Adjusted Regression Model 
controlling for Age, Sex, and 
Race 
 
 
OR 
95% CI 
OR 
95% CI 
Lower Upper Lower Upper 
Exposure       
Unexposed 1 (reference)   1 (reference)   
Exposed 3.97 2.43 6.50 2.21 1.34 3.64 
Age 
2-4 years 
5-11 years 
12-17 years 
N/A 
  
 
1 (reference) 
1.07* 
4.76 
 
 
0.71 
3.32 
 
 
1.61 
6.82 
Sex N/A      
Male    1 (reference)   
Female    0.73 0.57 0.93 
Race N/A      
White    1 (reference)   
African-American    0.44 0.33 0.59 
Others    0.82* 0.60 1.11 
*Non-significant  
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B. Comparison of Subjects Exposed to Atypical Antipsychotics by Drug 
(i) Demographics of Subjects Using Select Atypical Antipsychotic Agent 
Figure 4.2 shows the prevalence of subjects on each atypical antipsychotic agent during the study 
period. Among subjects who were exposed to any one of the five atypical antipsychotics 
(n=4,922), the largest number of the subjects had claims for risperidone while the fewest had 
claims for olanzapine. The demographics based on atypical antipsychotic use are found in Table 
4.6. Subjects having claims for olanzapine, quetiapine, and ziprasidone had a mean age of 13 
years while risperidone users were the youngest. Among each of the atypical antipsychotic users, 
there were more male than female users.  
Figure 4.2: Percentage of subjects using each atypical antipsychotic agent 
 
 
 
 
 
 
 
48.76% 
27.00% 
18.45% 
3.21% 
2.58% 
Risperidone 
Aripiprazole 
Quetiapine 
Ziprasidone 
Olanzapine 
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Table 4.6: Demographics of subjects using each atypical antipsychotic agent (n=4,992) 
Drug n 
Sex 
Males 
(%) 
Age (years) 
Mean 
(SD) 
Range  
 
2-4 (%) 5-11 (%) 12-17 (%) 
Aripiprazole 1329 
843 
(63.43) 
12.46 
(3.35) 
3-17 13 (0.98) 489 (36.79) 827 (62.23) 
Olanzapine 127 
107 
(84.25) 
13.02 
(3.29) 
5-17 0 43 (33.86) 84 (66.14) 
Quetiapine 908 
529 
(58.26) 
13.32 
(3.12) 
4-17 3 (0.33) 230 (25.33) 675 (74.34) 
Risperidone 2400 
1793 
(74.71) 
10.63 
(3.67) 
2-17 97 (4.04) 1286 (53.58) 1017 (42.38) 
Ziprasidone 158 
95  
(60.13) 
13.26 
(3.08) 
5-17 0 40 (25.32) 118 (74.68) 
 
(ii) Prevalence of Anti-diabetic Medication Use 
The prevalences of anti-diabetic medication use among the antipsychotic subgroups were 
computed and shown in Table 4.7. The highest prevalence of concomitant anti-diabetic 
medication use was among ziprasidone users (8.23%). Among olanzapine users, which were 
hypothesized to have highest prevalence of concomitant anti-diabetic medication use, only 
3.15% had claims for anti-diabetic agents. Risperidone users had the lowest prevalence of 
concomitant anti-diabetic claims (0.46%).  
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Table 4.7: Prevalence of anti-diabetic medication and antilipidemic medication use by drug 
Atypical Antipsychotic Agent Anti-diabetic (%) Antilipidemic (%) 
Aripiprazole (N=1329) 2.18 0.53 
Olanzapine (N=127) 3.15 0.79 
Quetiapine (N=908) 1.32 0.22 
Risperidone (N=2400) 0.46 0.21 
Ziprasidone (N=158) 8.23 1.27 
 
Logistic regression analyses: Table 4.8 shows the results of the adjusted and unadjusted logistic 
regression analyses. The regression model showed that individual atypical antipsychotic agent 
use was significantly associated with whether the subject received an anti-diabetic medication 
(χ2 = 53.57, df = 4, p-value < 0.0001). Risperidone users were found to have 0.14 (95% CI = 0.04 
- 0.45) times lower odds than olanzapine users to receive an anti-diabetic medication. 
Ziprasidone users were found to have 2.76 (95% CI = 0.88 - 8.67) times higher odds than 
olanzapine to receive an anti-diabetic medication but this was not significantly different from 
olanzapine users (p-value = 0.0829). Since race was not found to be significantly associated with 
whether the subjects received an anti-diabetic medication or not in the exposed group (χ2 = 3.19, 
df = 2, p-value = 0.2033), only age (χ2 = 15.16, df = 2, p-value = 0.0005) and sex (χ2 = 18.45, df 
= 1, p-value < 0.0001) were added to the regression model. After controlling for age and sex, 
antipsychotic use by agent was significantly associated with receipt of anti-diabetic medication 
claim (χ2 = 44.54, df = 4, p-value < 0.0001). Risperidone users had 0.15 (95% CI = 0.04 - 0.47) 
times lesser odds of receiving an anti-diabetic medication compared with olanzapine users. 
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Ziprasidone had the highest odds but it was not significantly different than olanzapine users (p-
value = 0.2158). 
Table 4.8: Regression analyses of concomitant anti-diabetic medication use 
 Unadjusted Regression Model 
Adjusted Regression Model 
controlling for Age, and Sex  
 OR 
95% CI 
OR 
95% CI 
Lower Upper Lower Upper 
Atypical 
Antipsychotic 
      
Olanzapine 1 (reference)   1 (reference)   
Aripiprazole 0.69* 0.24 1.98 0.56* 0.19 1.63 
Quetiapine 0.41* 0.13 1.30 0.29 0.09 0.94 
Risperidone 0.14 0.04 0.45 0.15 0.04 0.47 
Ziprasidone 2.76* 0.88 8.67 2.08* 0.65 6.65 
Age 
2-4 years 
5-11 years 
12-17 years 
N/A 
  
 
1 (reference) 
0.44* 
1.01* 
 
 
0.06 
0.13 
 
 
3.47 
7.64 
Sex N/A      
Male    1 (reference)   
Female    2.41 1.47 3.95 
* Non-significant 
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(iii) Prevalence of Antilipidemic Medication Use 
The prevalence of antilipidemic medication use among individual antipsychotic users is shown in 
Table 4.7. Risperidone users had the lowest prevalence of antilipidemic medication use (0.21%) 
which was similar to the prevalence of quetiapine (0.22%). Even though it was expected that 
olanzapine users would have the highest prevalence of antilipidemic medication use, ziprasidone 
users had the highest prevalence at 1.27%. 
Logistic regression analyses: The logistic regression analysis was not able to show that there was 
a significant difference in the prevalence of receiving an antilipidemic medication between the 
different antipsychotic agents (χ2
 
=6.49, df = 4, p-value < 0.1653).  Since age, sex, and race were 
not found to have a significant relationship with whether the subjects received an antilipidemic 
medication or not, they were not added into the regression model. The model showed that 
ziprasidone users had the highest odds of 1.61 (95% CI = 0.14 - 18.02), and risperidone and 
quetiapine users had the lowest odds of 0.26 (95% CI = 0.03 - 2.27) and 0.28 (95% CI = 0.02 - 
3.09), respectively, but none were significantly different from olanzapine users for antilipidemic 
medication use.  
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Chapter 5: DISCUSSION 
A. Main Findings 
The use of atypical antipsychotics has been correlated with weight gain, insulin resistance, and 
lipid abnormalities in adult populations.45 Draeger et al. assessed the prevalence of anti-diabetic 
and antilipidemic medication use among adult users of atypical antipsychotics, and reported that 
aripiprazole users had slightly higher odds than other atypical antipsychotic users of receiving an 
anti-diabetic or antilipidemic medication.
Though similar studies on anti-diabetic and antilipidemic mediation use have not been done in 
the pediatric population there is evidence that atypical antipsychotics cause substantial weight 
gain, insulin resistance, and metabolic syndrome.
46  
15,16,20,26,48,49 Studies have shown that increased 
weight gain and obesity during childhood are indicative of early development of metabolic 
syndrome, type 2 diabetes, and cardiovascular disease during adulthood.17,19  There are clinical 
guidelines describing how to address and treat children and adolescents who have type 2 
diabetes39 or hyperlipidemia.40
To the best of our knowledge, this is one of the few studies that has evaluated the prevalence of 
diabetic medication use among children exposed to atypical antipsychotics
 This raised the question of whether children on atypical 
antipsychotics who develop insulin resistance and lipid panel changes had to be started on anti-
diabetic and antilipidemic medications.  
20 and the only study 
to evaluate the prevalence of antilipidemic medication use among children. The prevalence of 
anti-diabetic medication use was significantly higher among children and adolescents with 
claims for atypical antipsychotics than those children and adolescents who were not using 
atypical antipsychotics. We found that about 1.40% of atypical antipsychotic users had anti-
 39 
 
diabetic medications compared with 0.32% among non-antipsychotic users. The use of anti-
diabetic medications among atypical antipsychotic users was more than four times the use of 
anti-diabetic agents among children not using atypical antipsychotics. This is similar to the 
results of the study by Andrade et al. which showed that the incidence of diabetes appeared to be 
more than four times higher among children and adolescents using atypical antipsychotics 
compared with those who were not.20 In this study, we also estimated the odds of receiving anti-
diabetic agents after controlling for demographic characteristics (i.e., age, sex, and race). We 
found that exposure to antipsychotics was still an important predictor of receipt of anti-diabetic 
prescriptions. Metformin was the most commonly prescribed anti-diabetic medication which is in 
accordance with the International Society for Pediatric and Adolescent Diabetes (ISPAD) 
guidelines on treating type 2 diabetes in children and adolescents.39
The prevalence of antilipidemic medication use was 0.35% among atypical antipsychotic users 
and 0.09% among non-users. The use of antilipidemic medications among children prescribed 
antipsychotics was almost four times higher than the prevalence of antilipidemic agents among 
non-users. Even after adjusting for demographic factors, the odds remained higher for 
antipsychotic users. According to the NCEP guidelines, pharmacotherapy should be reserved 
only for those children above 10 years of age with LDL levels exceeding 190 mg/dL.
  
43 
Pharmacologic therapy should be reserved for children less than 8 years of age with a dramatic 
elevation in cholesterol values (i.e., over 500 mg/dL). A study by Ford et al. showed that 0.8% of 
teenagers in the United States had LDL values above the cut-off of 190 mg/dL thereby requiring 
pharmacotherapy.42 This would imply that the true number of atypical antipsychotic users with 
hyperlipidemia is higher than 0.35% because only a small fraction of these children would have 
been started on a drug regimen.  
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Though the prevalence rates are relatively small, the clinical impact is relevant. Our study 
showed that 69 and 17 children out of the 4,922 subjects exposed to atypical antipsychotics were 
prescribed anti-diabetic and antilipidemic medications, respectively.  These numbers came from 
only one Medicaid database during the period of one year, therefore the numbers at a national 
level would be higher and could be a cause for concern. Studies have shown that children and 
adolescents with abnormalities in their glucose or lipid levels are at higher risk to develop 
hypertension and dyslipidemia as adults.39
Most of the demographic results of this study are consistent with published trials. In previous 
reports, the majority of the atypical antipsychotic users were males
 Children and adolescents prescribed atypical 
antipsychotics could be predisposed to develop diabetes, hyperlipidemia, and hypertension as 
adults. 
20, 28 and White28 which was 
consistent with our results of 68% males and 66% White. The mean age of children receiving 
atypical antipsychotics in our study was about 12 years which is less than the mean age of 15 
years reported by Fraguas et al.28
It was reported by McIntyre et al. that the odds of developing type 2 diabetes mellitus were 
higher for girls and adolescents.
 This could reflect the fact that the Fraguas study was 
conducted between 2001 and 2005, before aripiprazole, risperidone, quetiapine, and olanzapine 
received FDA approval for pediatric use and the use of these agents might have been reserved for 
older chlidren. 
29 The Agency for Healthcare and Research and Quality (AHRQ) 
does state that women are at higher risk of developing diabetes and that weight gain is a risk 
factor. Our study showed that females and adolescents had higher odds of receiving anti-diabetic 
medications. A limitation in our findings is that metformin can also be used off-label to treat 
polycystic ovarian syndrome (PCOS) in female children and adolescents50 and our study did not 
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exclude for subjects with PCOS. A study has shown that 5% of women develop PCOS and 
require pharmacotherapy.51 In addition; metformin has been prescribed for the treatment and 
prevention of atypical antipsychotic–induced weight gain and metabolic changes.
The same study by Fraguas et al. reported that the odds of developing dyslipidemia were higher 
for females and adolescents
52 
28
Atypical antipsychotics are being used in children and adolescents to treat various neuro-
psychiatric disorders (e.g., irritability associated with autism, tics, bipolar mania, 
schizophrenia).
 but our study showed that the odds of receiving antilipidemic 
medications were significantly higher for males and adolescents. Larger studies using data from 
multiple states are needed to obtain robust results.  
14 Even though some of the atypical antipsychotics are approved for pediatric use 
by the FDA, most are only approved for children as young as 10 years old. Risperidone is 
indicated for the treatment of irritability associated with autistic disorder in children as young as 
5 years old.53
Our study showed that the most commonly prescribed atypical antipsychotic was risperidone 
while the least commonly prescribed was olanzapine during the study period. A retrospective 
study by Pathak et al. of a state’s Medicaid administrative claims data from 2001-2005 reported 
that risperidone was the therapy initiated for most children while ziprasidone was the least 
common therapy initiated in new users.
 Our study showed that atypical antipsychotics were being used in children as 
young as 2 years old which indicates that these agents were being prescribed off-label in this 
young pediatric population.  
54 A possible explanation for the high use of risperidone 
could be that risperidone has been commercially available for a longer period of time and had 
received its pediatric indication earlier than other atypical antipsychotics. The use of ziprasidone 
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during the study by Pathak et al. was off-label. Over the years, the increasing use of ziprasidone 
may be reflective of published literature supporting the use of ziprasidone over agents with a 
higher propensity to cause metabolic effects (i.e., olanzapine).16,28 Our study has shown that the 
use of olanzapine among children was less frequent than risperidone which may be secondary to 
the number of studies reporting the harmful effects of olanzapine in children.
A study by Seida et al. showed that there were no major differences among olanzapine, 
risperidone, and quetiapine in insulin resistance.
26 
55 Another study by Correll et al. showed that 
olanzapine, and quetiapine had higher propensity to cause increase glucose levels.16 In contrast, a 
study by Cohen et al. reported that risperidone caused a greater glucose imbalance than 
olanzapine.56 There has been varying evidence on the propensity of each drug to cause glucose 
imbalance. Our study, which specifically looked at receipt of anti-diabetic medication, showed 
that risperidone users had the lowest prevalence of anti-diabetic medication use. Children and 
adolescents who were prescribed risperidone had lower odds than olanzapine users to receive an 
anti-diabetic medication. Interestingly, our study showed that ziprasidone users had a higher 
prevalence of anti-diabetic medication use than olanzapine users.  However, the OR was not 
found to be significantly different between olanzapine and ziprasidone users. The small sample 
sizes in the ziprasidone and olanzapine groups are limitations; hence there may not have been 
enough power to detect a significant difference. Ziprasidone use among children has not been 
studied as extensively as the other antipsychotics. Most of the studies were very short term and 
the longer studies had very limited sample sizes.26 Definitive conclusion regarding the metabolic 
effects of ziprasidone in children cannot be made until more studies are published in this area. 
Because of the cross-sectional nature of our study, it cannot be determined whether some of the 
ziprasidone users were children who had previously used olanzapine and were switched 
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secondary to metabolic adverse effects. Ziprasidone users in our trial were in a higher age 
category compared with olanzapine users. Because of these limitations, conclusions regarding 
ziprasidone cannot be made based on our data. 
The studies by Correll et al. and Fraguas et al. have shown that olanzapine was associated with 
the highest change in lipid levels among children and adolescents.16,28
This study adds to the findings of the trials that have been published. To the best of our 
knowledge, this is the only study that has looked at antilipidemic medication use in children and 
adolescents and one of the few studies that evaluated anti-diabetic medication use.
 Our study failed to 
identify differences in the odds of receiving antilipidemic medications among the various 
antipsychotic users. The prevalence was the highest among ziprasidone users, followed by 
olanzapine users, and the lowest among risperidone users. However, the differences were not 
statistically significant.  The failure to show a statistical difference could be because of the small 
number of children with antilipidemic mediation use, and hence there may not have been enough 
power to reach statistical difference. It is interesting to note that with just 17 children having 
antilipidemic prescriptions among antipsychotic users, a significance level of 0.1653 was 
reached. It may be a worthwhile attempt to replicate this study in a larger setting with more 
power.  
20 There are 
studies that have looked at adverse effects of antipsychotics or have addressed the development 
of type 2 diabetes mellitus. Several studies have evaluated the development of hyperlipidemia in 
children and adolescents on atypical antipsychotics,16 but none have reported actual antilipidemic 
medication use in this population. Since there were differences in the demographics between the 
groups, regression analyses controlling for these variables were done to see how they would 
affect the nature of the relationship. We also computed the prevalence of anti-diabetic and 
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antilipidemic medication use among a non-exposed group that was identified from the same 
Medicaid database to use as a comparator group. This is the only study that has assessed the odds 
of receiving anti-diabetic and antilipidemic medications among the various individual 
antipsychotics. Clinicians can use the prevalence and the odds of receiving anti-diabetic 
medication among atypical antipsychotic users to make informed decisions. The study has also 
set the groundwork for more studies in this area, possibly in larger, multicenter settings. 
B. Limitations 
Firstly, this is a cross-sectional study; hence we cannot establish any causal relationship between 
exposure to atypical antipsychotics and receipt of anti-diabetic or antilipidemic medications. This 
is not a longitudinal study looking at the long term effects of antipsychotic use. We have tried to 
address this limitation within the constraints of the study design by including only those subjects 
who had at least two paid claims for any one antipsychotic. 
 Secondly, because of the nature of the study, antipsychotic use is a crude measure. We cannot 
distinguish if subjects were switched from one antipsychotic before the study period. For 
example, if a patient developed diabetes while using olanzapine then was switched to ziprasidone 
and initiated on metformin, the anti-diabetic claim would have been included for this ziprasidone 
user. Also, it cannot be assumed that because a prescription for a medication was dispensed, it 
was consumed by the patient. 
Thirdly, there were varying sample sizes between the antipsychotic users and a small number of 
subjects with the outcomes of interest. Some of the sample sizes may have been too small to 
reach statistical significance.  
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A fourth limitation is potential confounders that were not controlled for. Factors such as physical 
activity, diet, and family history could affect the risk of receiving anti-diabetic and antilipidemic 
agents. A survey-based design would be more appropriate to capture such variables. We also did 
not adjust for pre-existing diabetes or hyperlipidemia. Confounding by indication could also be a 
potential limitation because metformin could have been used to treat other disorders (e.g., 
PCOS), or used to treat or prevent weight gain or metabolic effects of atypical antipsychotics and 
not just diabetes.  
Lastly, a major limitation is the limited generalizability of the study since this study used data 
from only a single state Medicaid pharmacy claims database. The results cannot be generalized 
to other pediatric populations, especially among those children not enrolled in Medicaid. 
C. Future Directions 
Further research should be done in this area to study the effects of all atypical antipsychotics. 
There is a need to carry out similar studies in a larger setting, i.e., a multi-state Medicaid study. 
This would ensure a larger sample and enough observations within each category to identify true 
differences. Studies should also examine the newer antipsychotics (e.g., lurasidone, asenapine) 
even though their use has not been significant among children and adolescents. Studies could 
also incorporate variables such as diet, physical activity, polypharmacy of antipsychotics, and 
concurrent use of other psychotropic medications, and study their individual relationship with the 
probability of receiving anti-diabetic or antilipidemic medications.  
More longitudinal studies looking at long term effects of exposure to atypical antipsychotics in 
children and adolescents are needed after excluding for pre-existing diabetes and hyperlipidemia. 
The results of these studies could help clinicians with informed decision making.  
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D. Conclusion 
In summary, the prevalence of anti-diabetic and antilipidemic medication use among children 
and adolescents using atypical antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole, 
and ziprasidone) was almost four times higher than the prevalence among children and 
adolescents not treated with the atypical antipsychotics. Risperidone users had lower odds of 
receiving anti-diabetic medication compared with olanzapine users. There were no significant 
differences between the individual atypical antipsychotics and receipt of antilipidemic agents. 
We also found that age, sex, and race were significant predictors of whether children on atypical 
antipsychotics received anti-diabetic and antilipidemic medications.  
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